Automated online safety margin (GLIOVIS) for glioma surgery model.

Autor: Mazevet M; Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland., Oberli C; Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland., Marinelli S; Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland., Zaed I; Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland., Bauer S; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland., Kaelin-Lang A; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.; Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Marchi F; Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland., Gardenghi R; Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland., Reinert M; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.; Department of Neurosurgery, Hirslanden Neurological and Spinal Surgery Center, St. Anna Clinic, Lucerne, Switzerland.; Department of Neurosurgery, Inselspital University Hospital, University of Bern, Bern, Switzerland., Cardia A; Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Apr 29; Vol. 14, pp. 1361022. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024).

An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress.

Autor: Igarashi T; Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan.; Department of Biosciences, School of Science, Kitasato University, Minami-ku, Sagamihara-city, Kanagawa, 252-0373, Japan., Mazevet M; Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Yasuhara T; Department of Late Effects Studies, Radiation Biology Center, Graduate School of Biostudies, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan., Yano K; Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Mochizuki A; Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan.; Department of Respiratory Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, 113-8519, Japan., Nishino M; Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan., Yoshida Y; Department of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan., Takamatsu N; Department of Biosciences, School of Science, Kitasato University, Minami-ku, Sagamihara-city, Kanagawa, 252-0373, Japan., Yoshimi A; Department of Biosciences, School of Science, Kitasato University, Minami-ku, Sagamihara-city, Kanagawa, 252-0373, Japan.; Division of Cancer RNA Research, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Shiraishi K; Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan.; Department of Clinical Genomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan., Kohno T; Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Hamamoto R; Division of Medical AI Research and Development, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan., Adachi J; Laboratory of Proteomics for Drug Discovery, Laboratory of Clinical and Analytical Chemistry, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki-city, Osaka, 567-0085, Japan., Zou L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, 02129, USA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02115, USA.; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, 27708, USA., Shiotani B; Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan. bshiotan@ncc.go.jp.

Publikováno v: Nature communications [Nat Commun] 2023 Aug 17; Vol. 14 (1), pp. 4991. Date of Electronic Publication: 2023 Aug 17.

EPAC1 inhibition protects the heart from doxorubicin-induced toxicity

Autor: Mélanie Gressette, Christophe Lemaire, Florence Lefebvre, A.M. Gomez, Mazevet M, B Crozatier, Philippe Mateo, Belleville T, D. Dayde, Marie-Catherine Vozenin, Eric Morel, Marion Laudette, Bachelot-Loza C, Llach A, Jingyao Chen, Catherine Rucker-Martin, Rodolphe Fischmeister, Maxance Ribeiro, A. Belhadef, Jean-Pierre Benitah, Frank Lezoualc'h

Rationale: The widely used chemotherapeutic agent Doxorubicin (Dox) induces cardiotoxicity leading to dilated cardiomyopathy and heart failure. This cardiotoxicity has been related to ROS generation, DNA intercalation, bioenergetic distress and cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971109331ada3c8e635c88b648b1417a
https://doi.org/10.1101/2021.06.16.448655

EPAC1 inhibition as a new therapeutic target in anthracyclines induced cardiotoxicity

Autor: Belhadef, A., Ribeiro, M., Mazevet, M., Laudette, M., Crozatier, B., Lezoualc’h, F., Benitah, J., Gomez, A., Morel, E., Lemaire, C.

Publikováno v: In Archives of Cardiovascular Diseases Supplements May 2021 13(2):216-216

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.